PHGE: Multiplikator Forward P/S BiomX

The projected P/S metric exhibits volatility as BiomX Inc. prepares its methods for combating resistant bacteria for sale. The 7.10 mark characterizes this parameter, with a closed-loop therapy based on phage cocktails serving as the foundation. However, the clinical testing stage is increasing laboratory expenses, which temporarily neutralizes the company's operating leverage.

PHGE BiomX Inc: Rasio kapitalisasi pasar marang pendapatan mangsa ngarep ing interval 21.08.2026 - 11.09.2026

Rincian analitis perusahaan BiomX Inc.

- rega saham lan target rega konsensus:

Kutipan saham BiomX|PHGE - Rega prakiraan analis

- informasi kapitalisasi pasar:

Kapitalisasi pasar PHGE|PHGE - Rega Tumbas Perusahaan

- statistik nilai buku emiten:

Aset Bersih saben Siji Saham BiomX|PHGE - Ekuitas Perusahaan|Rasio Nilai Pasar marang Nilai Buku biomx.com|PHGE - Total Aset Bisnis

- data liabilitas lan likuiditas perusahaan:

- data bathi bisnis lan rasio investasi:

PHGE - Penghasilan resik|Bathi mangsa ngarep BiomX Inc.|PHGE - Pangali rega marang bathi|Prakiraan rega marang bathi BiomX|PHGE - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA PHGE|PHGE - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone rolas wulan pungkasan BiomX|PHGE - Bathi saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan biomx.com|PHGE - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi saben saham kanggo taun ngarep BiomX Inc.

- rincian pendapatan lan dodolan:

PHGE - Pendapatan reged perusahaan|Prakiraan pendapatan perusahaan BiomX|PHGE - Rasio rega marang dodolan|Multiplikator Forward P/S PHGE

Ringkesan analitik perusahaan:BiomX Ltd PHGE

For BiomX Inc. (PHGE), which is restructuring its R&D portfolio to accelerate clinical trials, this indicator serves as a tool to verify market value relative to expected cash flows. By analyzing the forward price-to-sales ratio, an investor correlates current market capitalization with expected annual revenue, making it possible to distinguish fundamental asset undervaluation from systemic risks during the management's operational adaptation period.

Analisis perusahaan pesaing

Summit Therapeutics Inc. - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake MRNA (Moderna Inc)|Vaxcyte Corp - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Tarsus Corp TARS|CorMedix Inc. (CRMD) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep serestherapeutics.com (MCRB)|Rasio rega marang prakiraan pendapatan Spero Therapeutics, Inc.|Kapitalisasi marang prakiraan pendapatan SCYX (Scynexis)|Rasio rega marang prakiraan pendapatan AN2 Therapeutics, Inc. (ANTX)|Rasio kapitalisasi marang dodolan sing dikarepake polypid.com|Multiplikator Forward P/S LSB (LakeShore Biopharma Co.)|Iterum Therapeutics PLC - Rasio rega marang prakiraan pendapatan|BioPharma Bio - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake 60 Degrees Pharmaceuticals SXTP|Oragenics (OGEN) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep OpGen Corporation (OPGN)